TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* serum creatinine greater then or equal to 1.5~Exclusion Criteria:~* EF\<30~* Overt CHF~* Alkalemia~* Hypokalemia~* GFR\<20 cc/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran~* age 18-70~* a diagnosis of schizophrenia, schizophreniform, schizoaffective, or brief psychotic disorder determined by the Structured Clinical Interview for DSM-5~* no medication changes or psychiatric hospitalizations in the past month~* SFS modified raw score of no more than 75~Exclusion Criteria:~* substance use disorder in the past month, except mild to moderate cannabis use disorder~* illness affecting the nasal passages~* significant neurological/medical disorder~* pacemakers~* extensive dental work~* claustrophobia~* deafness~* inability to read~* currently participating in a psychosocial intervention targeting social functioning deficits~* currently taking high dose testosterone or estrogen/progesterone~* inability to complete VOT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Oxytocin (Type: EXPERIMENTAL): Dosages of oxytocin: 20IU or 40IU.
- Placebo (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Lens Deposits in Exfoliation Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of exfoliation syndrome, primary open angle glaucoma (POAG), or cataracts~Exclusion Criteria:~* Unable to provide or sign consent~* Pseudophakia~* Other prior intraocular surgery~* Other eye diseases other than refractive error

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- exfoliation syndrome (Type: None): patients with exfoliation syndrome
- POAG (Type: None): patients with primary open angle glaucoma (POAG)
- cataracts (Type: None): patients with cataracts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 \~ 65~* Patient with schizophrenia according to DSM-IV criteria~* Patient have signed on the informed consent, and well understood the objective and procedure of this study.~* Patient taking clozapine 3months or more~* Patient increased in weight more than 10 % of that of before antipsychotics use~Exclusion Criteria:~* Patient taking other antipsychotics with clozapine~* Patient in treatment of diabetes~* Patient in treatment of dyslipidemia~* Allergy or hypersensitivity to metformin~* Pregnant or breast-feeding female patient.~* Patient with severe medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metformin group (Type: EXPERIMENTAL): Metformin 500mg 1 tablet p.o. bid
- Placebo group (Type: PLACEBO_COMPARATOR): 1 tablet p.o. bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer confirmed by histology or cytology~* At least one measurable lesion~* Advanced disease refractory to standard therapy or for which no standard therapy exists~* Life expectancy of at least 3 months~Exclusion Criteria:~* Known secondary neoplasia or central nervous system (CNS) metastases; acute or chronic leukemia, lymphoma or multiple myeloma~* Body weight below 45 kg~* Female patients who are pregnant or breast feeding or adults of reproductive potential not employing effective method of birth control~* Confirmed diagnosis of HIV~* Insulin dependent diabetes mellitus / abnormal glucose tolerance test (GTT) / latent diabetes mellitus type I or II~* Chemotherapy or radiotherapy less than 4 weeks prior to entry~* Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)~* Participation in a clinical trial less than 30 days prior to entry in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AMT2003 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Weight-Bearing After Lapidus Arthrodesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject is at least 18 years of age with closed physeal plates at the time of screening.~* The intermetatarsal angle is greater than or equal to 10 degrees.~* The hallux valgus angle is greater than or equal to 25 degrees.~* The subject has foot pain/discomfort on the foot in question.~* The subject has activity limitations due to the foot in question.~* The subject agrees to comply with the requirements of the study and complete the study measures.~* The subject is willing and able to provide written informed consent.~Exclusion Criteria:~* The subject is pregnant.~* The subject is a current smoker.~* The subject has been clinically diagnosed with diabetes.~* The subject has been clinically diagnosed with peripheral neuropathy.~* The subject had been previously sensitized to titanium.~* The subject currently takes oral steroids or rheumatoid biologics.~* The subject has had previous surgery for hallux valgus on operative side.~* The subject has insufficient quantity or quality of bone to permit stabilization, conditions that retard healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease.~* The subject has a history of delayed or non-union for fracture or joint.~* The subject has an active, suspected or latent infection in the affected area.~* The subject will require a structural graft in the 1st TMT joint.~* The subject is scheduled to undergo a concomitant 2nd tarsometatarsal joint arthrodesis procedure.~* The subject is scheduled to undergo a same-day bilateral procedure.~* The subject cannot be scheduled for surgery within 3 months of the pre-operative exam.~* The subject has previously been enrolled into this study for a contralateral procedure.~* The subject is actively involved with a Workman's Compensation case.~* The subject is not expected to complete the study according to the investigation plan.~* The subject has been deemed physiologically or psychologically inadequate by the enrolling physician.~* The subject is: a prisoner, unable to understand what participation in the study entails, mentally incompetent, a known abuser of alcohol and/or drugs or anticipated to be non-compliant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Small Bone Intramedullary Nail (Type: None): All study participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Convective Pre-warming on Intra-operative Thermoregulatory Capabilities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-IV~* Other inclusion criteria as delineated in the TIGER anesthesia perioperative protocol~Exclusion Criteria:~* Inability to obtain written informed consent~* Inability to obtain core body temperature recordings~* Family history of malignant hyperthermia~* Preoperative temperature \> 38° C~* Other exclusion criteria as delineated in the TIGER anesthesia perioperative protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convective pre-warming (Type: EXPERIMENTAL): Undergo convective warming during the preoperative preparations, completed for a minimum of 60 minutes prior to entering the operating room
- Standard of care (Type: NO_INTERVENTION): Undergo standard of care, which includes providing each patient with blankets and sheets, as well as more blankets on patient request.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant Female Patients greater than or equal to 18 years of age~2. Induction of labor for a single live intrauterine pregnancy~3. Greater than or equal to 37 weeks gestational age~4. Cephalic presentation~5. 20 minute reassuring fetal heart rate (reactive nonstress test (NST))~6. Bishop score based on sterile vaginal exam of less than or equal to 6, for which the cervical dilation is less than or equal to 2 cm.~7. Equal to 3 or less uterine contractions over 10 minutes~Exclusion Criteria:~1. Previous uterine scar~2. Contraindication to vaginal delivery~3. Patients with preeclampsia~4. Grand multiparty - greater than or equal to 5 live births or stillbirths~5. Premature rupture of membranes~6. Suspected intrauterine growth restriction~7. Fetal anomalies~8. Contraindication to misoprostol (history of allergy to prostaglandins, glaucoma)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Oral misoprostol (Type: EXPERIMENTAL): oral misoprostol given 25 mcg every 2 hours
- Vaginal misoprostol (Type: ACTIVE_COMPARATOR): vaginal misoprostol given 25 mcg every 4 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Origin of Premature Atrial Beats Induced by Simulated Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of ECG-documented paroxysmal atrial fibrillation within the last 12 months and currently in sinus rhythm~* Scheduled for circumferential pulmonary venous isolation treatment~* 18 to 75 years of age~* Signed informed consent~Exclusion Criteria:~* Treated with class III anti-arrhythmic agents (at the moment of pulmonary venous isolation)~* Treated for obstructive sleep apnea~* Previous catheter ablation in the pulmonary veins or left atrium~* Severe structural heart disease~* Mental or physical disability precluding informed consent or compliance with the protocol~* Enrolled in another study that would confound the results of this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pulmonary vein isolation (Type: OTHER): Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index \> 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
- No intevention (Type: NO_INTERVENTION): Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index \< 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PIEB vs CEI for Labor Analgesia: An MLAC Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I \& II, Nulliparous and Multiparous, Spontaneous/Induced/Augmented Labor, Early active labor (cervix \<5 cm (if known)), Pain (VPS) \> 3, 18-45 years of age~Exclusion Criteria:~* \<37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption), Women who are participating in another study that will impact protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Part A Group 1 (Type: ACTIVE_COMPARATOR): CEI bupivacaine and CEI sufentanil
- Part A Group 2 (Type: ACTIVE_COMPARATOR): PIEB bupivacaine and PIEB sufentanil
- Part B Group 3 (Type: ACTIVE_COMPARATOR): CEI bupivacaine and PIEB sufentanil
- Part B Group 4 (Type: ACTIVE_COMPARATOR): PIEB bupivacaine and CEI sufentanil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed cutaneous T-cell non-Hodgkin lymphoma (CTCL)~* Relapsed or refractory disease, meeting 1 of the following criteria:~  * Progression of disease following 2 prior chemotherapies~ * Failure to respond to the second prior chemotherapy~* Measurable disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 3 months~* Serum creatinine \< 1.5 times upper limit of normal (ULN)~* Serum AST/ALT \< 2.5 times ULN~* Total bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL in patients with Gilbert syndrome)~* WBC count ≥ 3,000/mm³~* Platelet count ≥ 100,000/mm³~* Serum albumin \> 2.5 g/dL~* LVEF ≥ 45% by 2-D ECHO or MUGA scan~* Human antimurine antibody \< 1 μg/mL~* Patients with a history of electrocardiogram abnormalities, symptoms of cardiac ischemia, or arrhythmias must have a normal cardiac stress test (i.e., stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test)~* Must be willing to undergo venipuncture and central line placement~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No HBV surface antigen, HCV, or HIV antibody positivity~* No autoimmune disease or immunodeficiency (i.e., HIV)~* No history of uncontrolled concurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Ongoing or active cardiac disease (i.e., congestive heart failure, unstable angina pectoris, or cardiac arrhythmia)~ * Psychiatric illness and/or social situation that would preclude study compliance~* No other malignancies except treated basal cell or squamous cell carcinoma of the skin, or treated carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 3 weeks since prior systemic therapy for CTCL~* More than 6 months since prior chronic steroid therapy or chronic anti-coagulation therapy~* No prior therapy with anti-CD25 immunotoxin IMTOX25 and/or Ontak~* No other concurrent cancer chemotherapy, experimental therapy, investigational agent, or immunomodulating agent (including steroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- IMTOX25 at 2mg/m²/dose (Type: EXPERIMENTAL): Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is starting treatment with cetuximab at the WVU Cancer Center~* Patient has advanced (unresectable or metastatic) malignancy~* Patient is expected to remain on cetuximab treatment for at least 2 weeks after enrollment on study.~* Patients should be 18 years or older~* Patients should not have a known contraindication to topical pimecrolimus therapy~* Patients should have given written informed consent~* Sexually active men and women of child bearing potential agree to use an effective method of contraception during study participation and for three months afterwards.~* Negative pregnancy test for woman of child bearing potential~Exclusion Criteria:~* Known allergy to topical pimecrolimus.~* Patients with active or recent (within one month) infection in face~* Psoriasis, eczema or others skin conditions not related to cetuximab involving face~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pimecrolimus on Left vs. Placebo on Right (Type: EXPERIMENTAL): Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
- Pimecrolimus on Right vs. Placebo on Left (Type: EXPERIMENTAL): Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy